12:00 AM
 | 
Dec 24, 2012
 |  BC Week In Review  |  Company News  |  Deals

Acorda Therapeutics, Inc., Neuronex deal

Acorda completed its acquisition of Neuronex, which is developing a nasal spray formulation of diazepam for epilepsy, with a closing payment of $6.8 million. Acorda made an initial payment of $2 million to Neuronex in 1Q12 and an additional payment...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >